| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/01/1997 | WO1997015302A1 Pharmaceutical compositions of levo-enantiomers of medetomidine derivatives and their use |
| 05/01/1997 | WO1997015301A1 Method of adjusting the circadian rhythm of a mammal |
| 05/01/1997 | WO1997015300A2 Use of 4-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene for prophylaxis and treatment of sequelae of acute and chronic reduced circulation in the brain and neurodegenerative disorders |
| 05/01/1997 | WO1997015299A1 Relief and prevention of suffering conditions |
| 05/01/1997 | WO1997015298A1 Combination of ltd, receptor antagonists with glucocorticosteroids |
| 05/01/1997 | WO1997015297A1 Compositions and methods for buccal delivery of pharmaceutical agents |
| 05/01/1997 | WO1997015294A1 Transdermal therapeutic system (tts) for administering active substances for the treatment of drug dependency or drug addiction |
| 05/01/1997 | WO1997015293A2 Method of producing multi-layer medicaments in solid form for oral or rectal administration |
| 05/01/1997 | WO1997015289A1 Solubilisation methods |
| 05/01/1997 | WO1997015284A1 Ophthalmic cromolyn gel preparation |
| 05/01/1997 | WO1997015283A1 Topical compositions containing n-acetylcysteine and odor masking materials |
| 05/01/1997 | WO1997015282A1 Compositions for the treatment of dermatological disorders and methods for their use |
| 05/01/1997 | WO1997015281A1 Use of at least one beta-adrenergic agonist as a p substance antagonist |
| 05/01/1997 | WO1997015280A1 Use of at least one no synthase inhibitor for treating sensitive skin |
| 05/01/1997 | WO1997015269A2 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| 05/01/1997 | WO1997015225A1 Agent for treating neuro-degenerative disorders |
| 05/01/1997 | WO1997015191A1 Wet granulation formulation of a growth hormone secretagogue |
| 05/01/1997 | WO1997012601A3 Gel formulations containing growth factors |
| 05/01/1997 | WO1997012527A3 Use of threonine for the treatment of phenylketonuria |
| 05/01/1997 | WO1996028154A3 Use of anti-oestrogens as male contraceptives |
| 05/01/1997 | CA2235854A1 Method of inhibiting sleep apnea |
| 05/01/1997 | CA2235803A1 Method of adjusting the circadian rhythm of a mammal |
| 05/01/1997 | CA2235756A1 Peptide inhibitors of a phosphotyrosine-binding domain containing protein |
| 05/01/1997 | CA2235746A1 Relief and prevention of suffering conditions |
| 05/01/1997 | CA2235685A1 Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization |
| 05/01/1997 | CA2235684A1 Transdermal therapeutic system (tts) for administering active substances for the treatment of drug dependency or drug addiction |
| 05/01/1997 | CA2235621A1 Imidazole derivatives and their use as nitrogen monoxide synthase inhibitors |
| 05/01/1997 | CA2235614A1 Eye drops |
| 05/01/1997 | CA2235599A1 High fluorescence specific immune enhancing factor and methods of use for same |
| 05/01/1997 | CA2235575A1 Novel human cysteine protease |
| 05/01/1997 | CA2235548A1 Therapeutic use of hemoglobin in promoting wound healing |
| 05/01/1997 | CA2235510A1 Gnrh/reduced pseudomonas exotoxin conjugates |
| 05/01/1997 | CA2235509A1 In vitro growth of functional islets of langerhans and in vivo uses thereof |
| 05/01/1997 | CA2235495A1 Methods of preserving microorganisms |
| 05/01/1997 | CA2235490A1 Papyracillic acid, method for preparation and its use as synthon for bioactive substances |
| 05/01/1997 | CA2235487A1 Solubilisation methods |
| 05/01/1997 | CA2235481A1 Compositions and methods for treating bone deficit conditions |
| 05/01/1997 | CA2235402A1 Compositions and methods for buccal delivery of pharmaceutical agents |
| 05/01/1997 | CA2235396A1 Salts of n-(4-oxo-2-(1h-tetrazoyl-5-yl)-4h-1-benzopyran-8-yl)-4-(4-phenylbutoxy)benzamide |
| 05/01/1997 | CA2235371A1 Polymorphic forms of a growth hormone secretagogue |
| 05/01/1997 | CA2235368A1 Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
| 05/01/1997 | CA2234817A1 Wet granulation formulation of a growth hormone secretagogue |
| 05/01/1997 | CA2233966A1 4-oxa and 4-thia steroids |
| 05/01/1997 | CA2233882A1 Pseudomonas exotoxin as immunogenic carrier in synthetic conjugate vaccines |
| 05/01/1997 | CA2233862A1 17-alkyl-7-substituted-4-aza steroid derivatives |
| 05/01/1997 | CA2233861A1 Fibrinogen receptor antagonist |
| 05/01/1997 | CA2233075A1 Fluoro-substituted benzoylpropionic acid derivatives |
| 05/01/1997 | CA2232419A1 Stabilised pharmaceutical compositions containing dobutamine |
| 05/01/1997 | CA2232336A1 Pharmaceutical compositions of levo-enantiomers of medetomidine derivatives and their use |
| 05/01/1997 | CA2232241A1 Diagnosis of susceptibility to cancer and treatment thereof |
| 05/01/1997 | CA2229617A1 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| 05/01/1997 | CA2228054A1 Lubeluzole n-oxide |
| 05/01/1997 | CA2205534A1 Method, compositions and kits for increasing the bioavailability of pharmaceutical agents |
| 05/01/1997 | CA2188634A1 1ó,26 dihydroxy-d-homo-vitamin d3 |
| 05/01/1997 | CA2188381A1 Glycomimetics as selectin antagonists and pharmaceuticals having antiin flammatory activity |
| 05/01/1997 | CA2186412A1 Ethylamino carbazole melatonergic agents |
| 04/30/1997 | DE19541146A1 Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren Imidazole derivatives and their use as nitric oxide synthase inhibitors |
| 04/30/1997 | DE19541128A1 Stabilisierte schilddrüsenhormonhaltige Arzneimittel Stabilized thyroid hormone-containing drugs |
| 04/30/1997 | DE19540132A1 Stable lyophilisate of ifosfamide containing lactose as auxiliary material |
| 04/30/1997 | DE19539861A1 Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen Using 4-amino-4- (4-fluoro-benzylamino) -1-ethoxy-carbonylaminobenzen for the prophylaxis and treatment of the sequelae of acute and chronic cerebral hypoperfusion and neurodegenerative diseases |
| 04/30/1997 | DE19539743A1 Use of carotenoid, esp. beta-carotene, to inhibit histamine release |
| 04/30/1997 | CN1148855A Novel spiro [indole-pyrrolidine]derivatives as melatoninergic agonists, method for preparing same and use thereof as drug |
| 04/30/1997 | CN1148854A Tropane-z-aldoxine derivatives and preparation process and use thereof |
| 04/30/1997 | CN1148851A Dihydodibenzo isoquinolines diketone |
| 04/30/1997 | CN1148849A Process for preparing anhydrous and hydrate forms of antihistaminic pipeeridine derivatives, polymorphs and spseudormophs thereof |
| 04/30/1997 | CN1148843A Enhancement of the effect of drugs by deuteration |
| 04/30/1997 | CN1148811A Compound having antihypertensive, cardioprotective, anti-ischemic and antilipolytic functions |
| 04/30/1997 | CN1148810A Medicinal composition for treating glaucoma |
| 04/30/1997 | CN1148809A Ocular tension depressant |
| 04/30/1997 | CN1148808A Anti-acne composition |
| 04/30/1997 | CN1148807A Pyrimidine ortriazine carboxylic acid derivatives to be used as medicaments |
| 04/30/1997 | CN1148806A Transdermal delivery of anti-epileptic drugs |
| 04/30/1997 | CN1148805A Method for stabilizing duocarmycin derivatives |
| 04/30/1997 | CN1148804A 药物 Drug |
| 04/30/1997 | CN1148600A Seaweed polysaccharide trace-element complex and its preparation method and usage |
| 04/30/1997 | CN1148596A Noval crystal type anhydrous 7-([1 alpha, 5 alpha, 6 alpha]-6-amino-3-azabicyclo[3,1,0]hexyl-3-group)-6-fluorine-1-(2,4-difluorophenyl |
| 04/30/1997 | CN1148594A Piperidyl methyl oxazolidinone |
| 04/30/1997 | CN1148591A Preparation of tetrahydro-isoquinoyl compound and its composition, and medicinal use thereof |
| 04/30/1997 | CN1148590A Sulfuryl or sulfinyl benzoyl guanidine derivative |
| 04/30/1997 | CN1148493A High-energy oxygen anti-cancer guiding synthetic agent |
| 04/30/1997 | CN1148492A Treatment for arteriosclerosis and vitiligoidea |
| 04/30/1997 | CN1148491A Method for preparing medicinal composition in noval physical form containing heterocyclic amide derivative |
| 04/30/1997 | CN1034734C Azierythromycin crystal and its preparation method thereof |
| 04/30/1997 | CN1034733C Spiro piperidines and homologs which promote release of growth hormone |
| 04/30/1997 | CN1034732C Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders |
| 04/30/1997 | CN1034714C Beads having a core coated with an antifungal and a polymer |
| 04/29/1997 | US5625085 Immunology |
| 04/29/1997 | US5625079 Synthesizing psoralen compounds useful as intermediates |
| 04/29/1997 | US5625078 Processes for the production of 13-ether derivatives of milbemycins and novel intermediates therefor |
| 04/29/1997 | US5625072 Retroviral protease inhibiting compounds |
| 04/29/1997 | US5625067 Cyclopentane ether derivatives, processes for their production, and their pharmaceutical use |
| 04/29/1997 | US5625061 Graft=glycinamide riboncleotide formyl transferase |
| 04/29/1997 | US5625050 Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
| 04/29/1997 | US5625044 Methods for the preparation of pure homologous series of mono to tetra fatty acyl esters of sugars and pharmaceutical formulations useful in the treatment of cancer |
| 04/29/1997 | US5624963 Process for removing bile salts from a patient and compositions therefor |
| 04/29/1997 | US5624961 Benzylaminoethoxybenzene derivatives, production thereof and use thereof |
| 04/29/1997 | US5624960 Orally administrable drugs for the treatment of central dopamine deficiency conditions |
| 04/29/1997 | US5624957 Retinoid active compounds |
| 04/29/1997 | US5624955 Compounds that enhance the concentration of glutathione in tissues |
| 04/29/1997 | US5624953 Pharmaceutical compounds |